Enavate Sciences, a platform dedicated to supporting therapeutic companies advancing medicines and enabling technologies, and Venrock Healthcare, a fund dedicated to investing in publicly-held and privately-held healthcare companies, led a $200m Series B funding round in Upstream Bio, an operator of a biotech company intended to address allergic and inflammatory diseases, with participation from Bain Capital Life Sciences, Wellington Management, OrbiMed, Access Biotechnology, Decheng Capital, Altshuler Shaham Provident Funds, TCG X, HBM Healthcare Investments, Omega Funds and Samsara BioCapital. “Enavate is thrilled to be co-leading this important investment in Upstream Bio to advance the clinical development of UPB-101. We are excited to partner with Upstream to help improve the lives of patients with inflammatory diseases,” Edd Fleming, Enavate Sciences Managing Director and Executive Vice President.